The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Business Wire

Gilead Sciences Receives Subpoena from U.S. Department of Justice

Friday, June 10, 2011

Gilead Sciences Receives Subpoena from U.S. Department of Justice17:07 EDT Friday, June 10, 2011 FOSTER CITY, Calif. (Business Wire) -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has received a subpoena from the United States Attorney's Office for the Northern District of California requesting documents related to the manufacture, and related quality and distribution practices, of Atripla®, Emtriva®, Hepsera®, Letairis®, Truvada®, Viread® and our investigational fixed-dose combination of Truvada and EdurantTM. Gilead is cooperating in this civil and criminal investigation. About Gilead Sciences Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific. Emtriva, Hepsera, Letairis, Truvada and Viread are registered trademarks of Gilead Sciences, Inc.Atripla is a registered trademark of Bristol-Myers Squibb & Gilead Sciences, LLC.Edurant is a trademark of Tibotec Pharmaceuticals.For more information on Gilead Sciences, please visit the company's website at www.gilead.com or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000. Gilead Sciences, Inc.Patrick O?Brien, 650-522-1936 (Investors)Cara Miller, 650-522-1616 (Media)